



Memorandum Micro #198

To: UNCMC and Hillsborough Attending and Faculty Practice Physicians, Housestaff, Clinical Nurse Coordinators, Department Heads, and Supervisors

From: *KA* Kevin Alby, PhD, Associate Director
Clinical Microbiology/Molecular Microbiology Laboratories

HCU Herbert C. Whinna, MD, PhD, Medical Director
McLendon Clinical Laboratories

MHM Martha McGee, Director
McLendon Clinical Laboratories

Date: March 11, 2021

Subject: Change in Antimicrobial Susceptibility Testing Methodology for Enterobacteriaceae

Effective March 16th, 2021, the Microbiology lab will transition from the Kirby Bauer Disk Diffusion method to the Becton Dickinson Phoenix System for antimicrobial susceptibility testing of Enterobacteriaceae. Kirby Bauer will remain the primary method for antimicrobial susceptibility testing for other organisms at this time.

Antimicrobial susceptibility testing results will continue to be reported in accordance to guidelines set forth by the Clinical Microbiology Lab and the Anti-Infective Subcommittee of UNC Medical Center to promote antimicrobial stewardship and utilization best practices.

Antimicrobials tested include: Amikacin, Amoxicillin-Clavulanate, Ampicillin, Ampicillin-Sulbactam, Aztreonam, Cefazolin, Cefepime, Ceftazidime, Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Ceftriaxone, Ciprofloxacin, Ertapenem, Gentamicin, Levofloxacin, Meropenem, Meropenem-Vaborbactam, Minocycline, Nitrofurantoin, Piperacillin-Tazobactam, Tetracycline, Tigecycline, Tobramycin, Trimethoprim-Sulfamethoxazole.

Questions can be directed to the Microbiology Lab 984-974-1805 or Dr. Kevin Alby at kevin.alby@unchealth.unc.edu.